“I Need Help”—A mnemonic to aid timely referral in advanced heart failure

Journal of Heart and Lung Transplantation

Volumn 36, Issue 5, 2017, Pages 593-594

  Baumwol, Jay ^a  

^a FIONA STANLEY HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DIURETIC AGENT; NATRIURETIC FACTOR;

CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; KIDNEY DYSFUNCTION; LEFT VENTRICULAR ASSIST DEVICE; LETTER; LIVER DYSFUNCTION; PATIENT REFERRAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; TIME; HEART ASSIST DEVICE; NEEDS ASSESSMENT; ORGANIZATION AND MANAGEMENT;

HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; NEEDS ASSESSMENT; REFERRAL AND CONSULTATION;

EID: 85014011290     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2017.02.010     Document Type: Letter

References (14)

1. 1 Yancy, C.W., Jessup, M., Bozkurt, B., et al. ACCF/AHA guidelines for the management of heart failure. Circulation 128 (2013), e240–e327.
2. 2 Mehra, M.R., Canter, C.E., Hannan, M.M., et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant 35 (2016), 1–23.
3. 3 Kirklin, J.K., Naftel, D.C., Pagani, F.D., et al. Seventh INTERMACS annual report: 15,000 patients and counting. J Heart Lung Transplant 34 (2015), 1495–1504.
4. 4 Metra, M., Ponikowski, P., Dickstein, K., et al. Advanced chronic heart failure: a position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 9 (2007), 684–694.
5. 5 Pocock, S.J., Ariti, C.A., McMurray, J.J.V., et al. Predicting survival in heart failure: a risk score based on 39372 patients from 30 studies. Eur Heart J 34 (2013), 1404–1413.
6. 6 Barlera, S., Tavazzi, L., Franzosi, M.G., et al. Predictors of mortality in 6975 patients with chronic heart failure in the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico-Heart Failure Trial. Circ Heart Fail 6 (2013), 31–39.
7. 7 Allen, L.A., Felker, M., Pocock, S., et al. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail 11 (2009), 170–177.
8. 8 Lee, D.S., Austin, P.C., Stukel, T.A., et al. “Dose-dependent” Impact of recurrent cardiac events on mortality in patients with heart failure. Am J Med 122 (2009), 162–169.
9. 9 Poole, J.E., Johnson, G.W., Hellkamp, A.S., et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 359 (2008), 1009–1017.
10. 10 Levy, W.C., Mozaffarian, D., Linker, D.T., et al. The Seattle Heart Failure Model. Prediction of survival in heart failure. Circulation 113 (2006), 1424–1433.
11. 11 Lee, T.T., Chen, J., Cohen, D.J., et al. The association between blood pressure and mortality in patients with heart failure. Am Heart J 151 (2006), 76–83.
12. 12 Solomon, S.D., Anavekar, N., Skali, H., et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 112 (2005), 3738–3744.
13. 13 Abraham, W.T., Adams, K.F., Fonarow, G.C., et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications. J Am Coll Cardiol 46 (2005), 57–64.
14. 14 Anand, I.S., Fisher, L.D., Chiang, Y.T., et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107 (2003), 1278–1283.